Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
Faivre-Finn C, Falk S, Ashcroft L, Bewley M, Lorigan P, Wilson E, Groom N, Snee M, Fournel P, Cardenal F, Bezjak A, Blackhall F. Faivre-Finn C, et al. Among authors: ashcroft l. BMJ Open. 2016 Jan 20;6(1):e009849. doi: 10.1136/bmjopen-2015-009849. BMJ Open. 2016. PMID: 26792218 Free PMC article. Clinical Trial.
Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study.
Haslett K, Franks K, Hanna GG, Harden S, Hatton M, Harrow S, McDonald F, Ashcroft L, Falk S, Groom N, Harris C, McCloskey P, Whitehurst P, Bayman N, Faivre-Finn C. Haslett K, et al. Among authors: ashcroft l. BMJ Open. 2016 Apr 15;6(4):e010457. doi: 10.1136/bmjopen-2015-010457. BMJ Open. 2016. PMID: 27084277 Free PMC article.
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team. Faivre-Finn C, et al. Among authors: ashcroft l. Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20. Lancet Oncol. 2017. PMID: 28642008 Free PMC article. Clinical Trial.
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
Tay RY, Fernández-Gutiérrez F, Foy V, Burns K, Pierce J, Morris K, Priest L, Tugwood J, Ashcroft L, Lindsay CR, Faivre-Finn C, Dive C, Blackhall F. Tay RY, et al. Among authors: ashcroft l. Ann Oncol. 2019 Jul 1;30(7):1114-1120. doi: 10.1093/annonc/mdz122. Ann Oncol. 2019. PMID: 31020334 Free PMC article. Clinical Trial.
The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.
Wheatley-Price P, Ma C, Ashcroft LF, Nankivell M, Stephens RJ, White SC, Lorigan P, Thatcher N, Blackhall FH, Shepherd FA. Wheatley-Price P, et al. Among authors: ashcroft lf. Ann Oncol. 2010 Feb;21(2):232-237. doi: 10.1093/annonc/mdp300. Epub 2009 Aug 12. Ann Oncol. 2010. PMID: 19675093 Free article.
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R, Griffiths R, Lorigan P, Ashcroft L, Taylor P, Burt P, Lee L, Chittalia A, Harris M, Faivre-Finn C, Thatcher N, Blackhall F. Califano R, et al. Among authors: ashcroft l. Lung Cancer. 2011 Sep;73(3):338-44. doi: 10.1016/j.lungcan.2011.01.001. Epub 2011 Feb 5. Lung Cancer. 2011. PMID: 21296449 Clinical Trial.
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).
Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. Booton R, et al. Among authors: ashcroft l. Ann Oncol. 2006 Jul;17(7):1111-9. doi: 10.1093/annonc/mdl078. Epub 2006 Apr 7. Ann Oncol. 2006. PMID: 16603599 Free article. Clinical Trial.
45 results